Recap: PRA Health Sciences Q4 Earnings

 

Shares of PRA Health Sciences PRAH rose 20.6% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 0.65% year over year to $1.55, which beat the estimate of $1.47.

Revenue of $873,458,000 rose by 9.15% year over year, which beat the estimate of $829,020,000.

Outlook

PRA Health Sciences hasn't issued any earnings guidance for the time being.

PRA Health Sciences hasn't issued any revenue guidance for the time being.

Technicals

Company's 52-week high was at $137.88

Company's 52-week low was at $58.67

Price action over last quarter: Up 35.55%

Company Overview

PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider.

Posted In: EarningsNewsBZI-Recaps
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...